EXO:EURONEXT AMSTERDAMEXOR N.V. Analysis

Exousia Bio’s share price has slipped from its recent support around $0.44 to $0.36, leaving the 20‑day SMA (≈$0.44) as a key technical barrier. The RSI sits near 68, signaling an overbought condition, while the MACD has turned bearish with a negative histogram, suggesting downward momentum. Volatility is elevated at roughly 57% over the past month and beta is effectively zero, indicating the stock moves independently of broader market swings. A historic max drawdown of about 66% underscores the price’s susceptibility to sharp declines.
Fundamentally, the company reports no revenue, a negative EBITDA of $‑280k, and a modest book value of $0.31 per share, resulting in a price‑to‑book ratio just above 1. The DCF‑derived fair value of roughly $0.015 is dramatically lower than the current market price, highlighting a substantial overvaluation. With zero cash on hand, no dividend, and a sector label of Consumer Defensive that belies its biotech reality, the firm faces high regulatory and execution risk, compounded by thin trading volumes that raise liquidity concerns.